Skip to search formSkip to main contentSkip to account menu

TP53 Mutational signature for aristolochic acid: an environmental carcinogen

TLDR
The unique TP53 mutational signature for AA can be used to explore the hypothesis that botanical products containing this human carcinogen and nephrotoxin are responsible, in part, for the high prevalence of UUC and chronic renal disease in countries where Aristolochia herbal remedies traditionally have been used for medicinal purposes.
View on Wiley (opens in a new tab)

TP53 mutation profile in chronic lymphocytic leukemia: evidence for a disease specific profile from a comprehensive analysis of 268 mutations

TLDR
The mutational profile was not different in the cohorts with and without previous therapy, suggesting that the mechanism underlying the development of mutations may be similar, independent of treatment.
View on Nature (opens in a new tab)

Evaluation of TP53 mutations with the AmpliChip p53 research test in chronic lymphocytic leukemia: Correlation with clinical outcome and gene expression profiling

TLDR
A high percentage of TP53 mutations are found in CLL with unfavorable outcome and a significant association between TP53 aberrations and del(17p) was recorded, and specific gene expression profiles are recognized for TP53 alterations.
View on Wiley (opens in a new tab)

Strong p53 Expression Is an Independent Predictor of Outcome in De Novo Diffuse Large B Cell Lymphoma (DLBCL) Treated with Either CHOP or CHOP-R.

TLDR
Strong p53 protein expression correlates with p53 mutations and is an independent prognostic factor for patients with DLBCL even when treated with CHOP-R, and the prognostic impact of p53 is not diminished in the era of CHOP, identifying a subgroup of patients with inferior survival.
View via Publisher (opens in a new tab)

The clinical relevance of p53 isoforms modifying the effects of p53 mutation on survival from breast cancer

TLDR
Nine splice variants of p53 in breast cancer have been identified, with full length p53, p53beta and p53alpha being identified.
View via Publisher (opens in a new tab)

Inactivation of TP53 correlates with disease progression and low miR-34a expression in previously treated chronic lymphocytic leukemia patients.

TLDR
A complete disruption of TP53 function, either by a combination of point mutations and/or del17p, was associated with a high risk for disease progression and progression-free survival of patients with a heterozygous TP53 mutation was not significantly different from patients with an completely intact TP53 locus.
View on PubMed (opens in a new tab)

TP53 Mutations and Outcome After Fludarabine and Cyclophosphamide (FC) or FC Plus Rituximab (FCR) in the CLL8 Trial of the GCLLSG.

TLDR
In conclusion, 17p deletion and TP53 mutation remain powerful prognostic markers after 1 st line FC and FCR treatment in CLL and when considering the genetic profile and treatment in a multivariate model, FCR improves PFS and OS compared to FC in C LL.
View via Publisher (opens in a new tab)

TP53 mutation analysis in chronic lymphocytic leukemia: comparison of different detection methods

TLDR
It is shown that in CLL patients carrying low-proportion TP53 mutation, the more sensitive approach, e.g., ultra-deep NGS, might be more appropriate and has the potential to overcome shortcomings of methods currently used, allows the detection of minor proportion mutations, and represents thus a promising methodology for near future.
View on Springer (opens in a new tab)

TP53 abnormalities in chronic lymphocytic leukemia exhibit a disease specific profile: meta-analysis of 270 mutations.

TLDR
The mutational profile was not different in the cohorts with and without prior therapy suggesting that the mechanism underlying the development of mutations may be similar independent of treatment.
View via Publisher (opens in a new tab)

Clinical Impact of TP53 Gene Mutations in Diffuse Large B-Cell Lymphoma (DLBCL): An International DLBCL Rituxan-CHOP Consortium Program Study.

TLDR
The importance of TP53 mutational profile for predicting clinical outcome is demonstrated as median survival was significantly improved for Rituxan-CHOP treated DLBCL patients with mutations in the loop-sheet-helix motifs andMultivariate analysis confirmed that TP53 mutations and activated B-cell-like (ABC) subtype classification were independent predictors of OS with a hazard ratio of 0.69.
View via Publisher (opens in a new tab)
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)